Table 3:
Adjusted sensitivity and secondary analyses 1
| No. of patients 2 |
Metoprolol Events (IR) |
Carvedilol Events (IR) |
HR (95% CI) | |
|---|---|---|---|---|
|
| ||||
|
Primary Analysis
|
24,239 | 8,150 (33.5) | 8,576 (33.4) | 0.97 (0.94, 1.01) |
|
Subgroup analysis
3
|
||||
| Male | 9,408 | 3,279 (37.2) | 3,472 (36.1) | 0.98 (0.94, 1.03) |
| Female | 14,739 | 4,965 (32.1) | 5,077 (31.8) | 0.99 (0.95, 1.03) |
| Age > 80 years | 8,901 | 2,945 (36.6) | 3,051 (37.9) | 0.96 (0.91, 1.01) |
| Digoxin or spironolactone use | 4,286 | 1,426 (33.5) | 1,415 (31.8) | 1.03 (0.96, 1.11) |
| Recent hospitalization (30 days) | 14,436 | 4,654 (32.1) | 5,022 (32.8) | 0.95 (0.91, 0.99) |
|
Sensitivity analysis
|
||||
| Intention to treat analysis | 24,239 | 9,683 (26.9) | 9,716 (28.1) | 0.98 (0.95, 1.01) |
| Broad HF definition 3 | 56,060 | 19,878 (31.6) | 20,920 (31.7) | 0.97 (0.95, 0.99) |
|
Secondary Outcomes
|
||||
| Insulin initiation 3,4 | 11,840 | 2,676 (16.3) | 2,845 (16.3) | 0.98 (0.93, 1.03) |
| Second-line therapy initiation 3,5 | 3,754 | 1,549 (41.2) | 1,641 (44.4) | 0.94 (0.87, 1.00) |
| Hyperglycemic hospitalization | 24,239 | 3,396 (9.8) | 3,658 (9.8) | 0.99 (0.94, 1.03) |
| Emergency room visit | 24,239 | 868 (2.3) | 962 (2.3) | 0.97 (0.88, 1.06) |
| Severe hyperglycemic event 6 | 24,239 | 3,822 (11.2) | 4,151 (11.3) | 0.98 (0.93, 1.02) |
Abbreviations: CI: Confidence Interval; IR: Incidence Rates per 100 person-years of follow up; HF Heart Failure
1
Analyses were adjusted using propensity score matching. See text for details.
2
In each group (represents the number of matched pairs).
3
Propensity score was re-estimated and patients were re-matched
4
Comprised of insulin naïve patients
5
Initiation of second-line antidiabetic therapy was assessed in patients who were on metformin monotherapy at baseline.
6
Composite of inpatient or emergency department visits relating to hyperglycemia; see Appendix Table 1 for codes.